Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interventions for olanzapine-related metabolic syndrome in schizophrenia
ChiCTR2000031979Phase 3Not yet recruiting
- Sponsor
- The Affiliated Brain Hospital of Guangzhou Medical University
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of olanzapine, berberine and perospirone in cardiometabolic risk (CMR), schizophrenia and schizoaffective disorder (3 arms), sponsored by The Affiliated Brain Hospital of Guangzhou Medical University. Primary endpoints: Body composition, Cranial MRI and 4 more. Planned start May 2020; status: not yet recruiting.
02
Drugs
olanzapineberberineperospirone
03
Conditions
cardiometabolic risk (CMR)schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on ChiCTR2000031979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031979.